摘要
目的比较不同胰岛素强化治疗方案治疗2型糖尿病的临床疗效。方法60例符合入组标准的2型糖尿病患者按随机数字表分为门冬胰岛素30强化治疗组（I组）与甘精胰岛素强化治疗组（Ⅱ组），每组各30例，门冬胰岛素30强化治疗组皮下注射门冬胰岛素30，3次／d，甘精胰岛素强化治疗组睡前皮下注射甘精胰岛素，1次／d，两组均治疗14d，记录血糖达标时间，观察低血糖发生隋况，进行胰岛素抵抗指数（HOMA-IR）、β细胞分泌功能指数（HOMA-8）检测，比较两组临床疗效。结果I组和Ⅱ组治疗后空腹血糖、餐后2h血糖、糖化血红蛋白、HOMA．IR、HOMA-B分别为（6．0±0．9）mmol／L比（5．4±1．1）mmol／L，（7．4±1．9）mmol／L比（6．6±2．3）mmol／L，（6．2±1．7）％比（6．0±1．9）％，（1．11±0．32）比（1．0l±0．35），（5．23±1．63）比（5．46±1．41），I组和Ⅱ组治疗后空腹血糖、餐后2h血糖、糖化血红蛋白、HOMA—IR均比治疗前明显降低，差异有统计学意义，I组和Ⅱ组治疗后HOMA—β均比治疗前明显升高，差异有统计学意义，两组治疗前后空腹血糖、餐后2h血糖、糖化血红蛋白、HOMA—IR、HOMA—β差异无统计学意义，I组和Ⅱ组血糖达标时间为（6．5±2．8）d比（6．2±2．5）d，差异无统计学意义，I组和Ⅱ组低血糖发生率为20％（6／30）比3％（1／30），差异具有统计学意义。结论门冬胰岛素30强化治疗与甘精胰岛素强化治疗2型糖尿病均能安全平稳控制血糖，增强胰岛B细胞功能，减轻胰岛素抵抗，但甘精胰岛素的低血糖发生率明显降低，甘精胰岛素是使血糖安全达标的理想胰岛素。
Objective To compare efficacy of different insulin intensive treatment in the treatment of type 2 diabetes,to provide a reference for the programming of intensive treatment of diabetes. Methods 60 type 2 diabetes patients met inclusion criteria were divided into insulin aspart 30 intensive treatment group （ I group） and insulin glargine intensive treatment group（ II group） by random number table ,30 cases of each group, I group was given sub- cutaneous injection of insulin aspart 30, rid, II group was given subcutaneous injection of insulin glargine at bedtime, qd. Both groups were treated for 14d, record the time of blood glucose control, observed the occurrence of low blood sugar, detected the HOMA-IR, HOMA-β and clinical efficacy. Results After treatment, the fasting glucose,2h postprandial blood glucose, glycosylated hemoglobin, HOMA-IR, HOMA-β of I group and II group were （6.0 ± 0.9） mmol/L vs （5.4 ±1.1 ）mmool/L, （7.4 ±1.9） mmo]/L vs （6.6± 2.3 ） retool/L, （6.2 ± 1.7 ） % vs （ 6.0 ±1.9 ） %, （ 1.11 ± 0.32） vs （ 1. 01 ±0.35 ）, （5.23 ± 1.63 ） vs （5.46 ± 1.41 ）, the fasting glucose,2h postprandial blood glu- cose, glycosylated hemoglobin, HOMA-IR of I and I/group after treatment compared with those before treatment, the differences were statistically significant. The HOMA-β of I and 11 group was significantly higher than that before treatment, the difference was statistically significant. The fasting blood glucose ,2h postprandial blood glucose, glycosy- lated hemoglobin, HOMA-IR, HOMA-13 before and after treatment between two groups was not significantly different, the time of blood glucose control between I and II group were （6.5 ±2.8 ） d vs （ 6.2 ± 2.5 ） d, the difference was not statistically significant,the low blood sugar of I and group II was 20% （6/30） vs 3% （1/30） ,there was statisti- cally significant difference. Conelusiort The insulin aspart 30 and insulin glargine intensive treatment all can control blood sugar, increase insulin β-cell function, reduce insulin resistance in the treatment of type 2 diabetes, but insulin glargine significantly reduced the incidence of hypoglycemia and insulin glargine is the ideal insulin for blood glucose security control.
出处
《中国基层医药》
CAS
2013年第7期988-990,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病
2型
胰岛素
长效
重组蛋白质类
注射
皮下
Diabetes mellitus, type 2
Insulin,long-actlng
Recombinant proteins
Injections, subcutaneous
